The combination of CXCL11 encoded oncolytic VACV and PD-L1 blockade synergistically enhanced the therapeutic efficacy by increasing T-cell infiltration into the tumor and upregulating the expression of PD-L1 (88). The gene discussed is CXCL11; the disease is neoplasm.